Lauren E. Abrey
Roche (Switzerland) · 333 works · 26,372 citations · h-index 83
Top works
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
- Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
- Treatment for Primary CNS Lymphoma: The Next Step
- Long-term survival in primary CNS lymphoma.
- Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
- Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model
- High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib
- Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma
- Rituximab, Methotrexate, Procarbazine, and Vincristine Followed by Consolidation Reduced-Dose Whole-Brain Radiotherapy and Cytarabine in Newly Diagnosed Primary CNS Lymphoma: Final Results and Long-Term Outcome
- Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
- Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08
- Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas
- Long-Term Follow-Up of High-Dose Methotrexate-Based Therapy With and Without Whole Brain Irradiation for Newly Diagnosed Primary CNS Lymphoma
- Intensive Methotrexate and Cytarabine Followed by High-Dose Chemotherapy With Autologous Stem-Cell Rescue in Patients With Newly Diagnosed Primary CNS Lymphoma: An Intent-to-Treat Analysis
- The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma
- Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
- Phase I Study of Intraventricular Administration of Rituximab in Patients With Recurrent CNS and Intraocular Lymphoma
- Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide
- Primary CNS lymphoma with intraocular involvement